LEI-106
LEI-106 is a potent, dual sn-1-Diacylglycerol lipase α (DAGL-α) /ABHD6 inhibitor with an IC50 of 18 nM for DAGL-α and a Ki of 0.8 μM for ABHD6. LEI-106 inhibits the hydrolysis of [14C]-sn-1-oleoyl-2-arachidonoyl-glycerol, the natural substrate of DAGL-α, with a Ki of 0.7 μM[1].
Product Specifications
CAS Number
1620582-23-1
UNSPSC
12352005
Target
DAGL; MAGL
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/lei-106.html
Purity
99.9
Solubility
10 mM in DMSO
Smiles
OC(CN(CC1=CC=C(OC2=CC=CC=C2)C=C1)S(C3=CC=C4OC(C)(CCC4=C3)C)(=O)=O)=O
Molecular Formula
C26H27NO6S
Molecular Weight
481.56
References & Citations
[1]Janssen FJ, et al. Discovery of glycine sulfonamides as dual inhibitors of sn-1-diacylglycerol lipase α and α/β-hydrolase domain 6. J Med Chem. 2014;57 (15) :6610-6622.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
